Phaseline

Companies › Biohaven Pharmaceuticals

Biohaven Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 3; Neurology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
taldefgrobep alfa
Engineered IGF-1 analog; recombinant human IGF-1 receptor agonist
IGF1Phase 3Spinal Muscular AtrophyDec 2027
troriluzole
Glutamate release inhibitor
–Phase 3Spinocerebellar Ataxias–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03701399troriluzolePhase 3Spinocerebellar AtaxiasNeurologyFeb 2022
NCT05337553taldefgrobep alfaPhase 3Spinal Muscular AtrophyNeurologyDec 2027

From the company's SEC filings

Cash and short-term investments of $161m on 2026-09-30; operating cash outflow about $459m a year; runway about 4 months at that burn, to Feb 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

IGF1 (1)

Companies with the same targets

–

Companies built like this

Annovis Bio Larimar Therapeutics Immunic Alpha Cognition NervGen Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.